{"id":942330,"date":"2026-03-05T12:02:15","date_gmt":"2026-03-05T17:02:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/"},"modified":"2026-03-05T12:02:15","modified_gmt":"2026-03-05T17:02:15","slug":"arcturus-therapeutics-to-attend-upcoming-investor-conference-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/","title":{"rendered":"Arcturus Therapeutics to Attend Upcoming Investor Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Arcturus Therapeutics to Attend Upcoming Investor Conference<\/b><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nArcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida:<\/p>\n<p><b>Leerink Partners 2026 Global Healthcare Conference (Fireside Chat)<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nWednesday, March 11, 2026 (11:20 a.m. ET)<\/p>\n<\/li>\n<\/ul>\n<p>\nWebcast link can be found under Investor Relations\/Events section of Arcturus\u2019 <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54439278&amp;newsitemid=20260305745864&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3149daf6901b9dfe8b36d8d863427050\">website<\/a>.<\/p>\n<p><b>About Arcturus<\/b><\/p>\n<p>\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR<sup>\u00ae<\/sup> lipid-mediated delivery, (ii) STARR<sup>\u00ae<\/sup> mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE<sup>\u00ae<\/sup>, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus\u2019 pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus&#8217; technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ArcturusRx.com&amp;esheet=54439278&amp;newsitemid=20260305745864&amp;lan=en-US&amp;anchor=www.ArcturusRx.com&amp;index=2&amp;md5=108d1982806d94d7bafdd0f23dfa0fb7\">www.ArcturusRx.com<\/a>. Please connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Farcturusrx&amp;esheet=54439278&amp;newsitemid=20260305745864&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=4ae7fd03bcf7d2827449860be8d16bad\">X<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farcturus-therapeutics&amp;esheet=54439278&amp;newsitemid=20260305745864&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=2fc9a5dce8856340fffa429c90d31ed6\">LinkedIn<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260305745864\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260305745864\/en\/<\/a><\/span><\/p>\n<p><b>Arcturus Therapeutics<br \/>\n<\/b><br \/>Public Relations &amp; Investor Relations<br \/>\n<br \/>Neda Safarzadeh<br \/>\n<br \/>VP, Head of IR\/PR\/Marketing<br \/>\n<br \/>(858) 900-2682<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@ArcturusRx.com\">IR@ArcturusRx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California Florida United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> COVID-19 Infectious Diseases Genetics Clinical Trials Health Technology Biotechnology Other Health Health Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260305745864\/en\/2738828\/3\/arcturus-logo-blueback_%282%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Arcturus Therapeutics to Attend Upcoming Investor Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations\/Events section of Arcturus\u2019 website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u00ae &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arcturus Therapeutics to Attend Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942330","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcturus Therapeutics to Attend Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcturus Therapeutics to Attend Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Arcturus Therapeutics to Attend Upcoming Investor Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations\/Events section of Arcturus\u2019 website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u00ae &hellip; Continue reading &quot;Arcturus Therapeutics to Attend Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T17:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcturus Therapeutics to Attend Upcoming Investor Conference\",\"datePublished\":\"2026-03-05T17:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/\"},\"wordCount\":345,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/\",\"name\":\"Arcturus Therapeutics to Attend Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-03-05T17:02:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcturus Therapeutics to Attend Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcturus Therapeutics to Attend Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/","og_locale":"en_US","og_type":"article","og_title":"Arcturus Therapeutics to Attend Upcoming Investor Conference - Market Newsdesk","og_description":"Arcturus Therapeutics to Attend Upcoming Investor Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations\/Events section of Arcturus\u2019 website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u00ae &hellip; Continue reading \"Arcturus Therapeutics to Attend Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-05T17:02:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcturus Therapeutics to Attend Upcoming Investor Conference","datePublished":"2026-03-05T17:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/"},"wordCount":345,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/","name":"Arcturus Therapeutics to Attend Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-03-05T17:02:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260305745864r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-attend-upcoming-investor-conference-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcturus Therapeutics to Attend Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942330"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942330\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}